Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention

Aphasia Clinical Trial

Official title:

Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03662295
• Other study ID #: SMART
• Status: Completed
• Start date: September 3, 2018
• Est. completion date: November 13, 2019

Study information

• Verified date: March 2021
• Source: Quality Living, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Stroke-like migraine attacks after radiation therapy-also known as SMART syndrome-constitute a rare condition typically characterized by headache, seizures, vision abnormalities, hemiparesis, and aphasia. The condition usually resolves within a few days or weeks of onset with no residual impairments. However, resolution in some cases extends over a period of months rather than weeks and may be incomplete. The purpose of this case report is to provide an in-depth description of the progression of changes in cognitive and language functioning for a person exhibiting SMART syndrome characterized by slow recovery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: November 13, 2019
• Est. primary completion date: November 13, 2019
• Gender: All
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• exhibit cognitive and language deficits secondary to SMART syndrome
• be a former or current client of Quality Living, Inc., Omaha, Nebraska
• be a native speaker of English Exclusion Criteria: -

Related Conditions & MeSH terms

• Aphasia
• Migraine Disorders

Intervention

Behavioral:
• Language treatment
Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.

Locations

Country	Name	City	State
United States	Quality Living, Inc.	Omaha	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
Quality Living, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardized assessment	Aphasia Quotient of the Western Aphasia Battery - Revised	Change from baseline at 6 months
Secondary	Spoken picture description	Spoken language sample elicited through a request to describe events depicted in a Norman Rockwell drawing.	Change from baseline at 6 weeks, 10 weeks, 14 weeks, 20 weeks, and 26 weeks
Secondary	Written picture description	Written language sample elicited through a request to write about events depicted in a Norman Rockwell drawing.	Change from baseline at 6 weeks, 10 weeks, 14 weeks, 20 weeks, and 26 weeks